Colorectal cancer is a heterogeneous disease that develops via stepwise accumulation of
well-characterized genetic and epigenetic alterations. We review the genetic changes …

Background The role of adjuvant chemotherapy for patients with rectal cancer after
preoperative (chemo) radiotherapy and surgery is uncertain. We did a meta-analysis of …

The number of deaths from colorectal cancer in Japan continues to increase. Colorectal
cancer deaths exceeded 50,000 in 2016. In the 2019 edition, revision of all aspects of …

Background Despite improvements in multidisciplinary management, patients with biliary
tract cancer have a poor outcome. Only 20% of patients are eligible for surgical resection …

Background Patients who have residual invasive carcinoma after the receipt of neoadjuvant
chemotherapy for human epidermal growth factor receptor 2 (HER2)–negative breast cancer …

Background Since 2004, a regimen of 6 months of treatment with oxaliplatin plus a
fluoropyrimidine has been standard adjuvant therapy in patients with stage III colon cancer …

Colorectal cancer (CRC) is the most common tumour type in both sexes combined in
Western countries. Although screening programmes including the implementation of faecal …

Background We evaluated capecitabine (an oral fluoropyrimidine) and oxaliplatin (a
platinum compound) as alternatives to infused fluorouracil and cisplatin, respectively, for …

Colorectal cancer (CRC) is the third most common tumour in men and the second in women,
accounting for 10% of all tumour types worldwide. Incidence is higher in males (ratio: 1.4) …

Background A prospective, pooled analysis of six randomised phase 3 trials was done to
investigate disease-free survival regarding non-inferiority of 3 months versus 6 months of …